Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
5
|
pubmed:dateCreated |
1998-11-24
|
pubmed:abstractText |
While most of the focus in cancer immunology is on CD8+ cytotoxic T lymphocyte responses, recent evidence indicates that CD4+ T cells are an equally critical component of the antitumor immune response. Successful immunity to cancer will therefore require activation of tumor-specific CD4+ T cells. Tumor antigens recognized by CD4+ T cells that are restricted by MHC class II are beginning to be defined in both murine and human tumors. These will provide the basis for new generations of antigen-specific tumor vaccines.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Oct
|
pubmed:issn |
0952-7915
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
10
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
588-94
|
pubmed:dateRevised |
2005-11-16
|
pubmed:meshHeading |
pubmed-meshheading:9794842-Animals,
pubmed-meshheading:9794842-Antigens, Neoplasm,
pubmed-meshheading:9794842-CD4-Positive T-Lymphocytes,
pubmed-meshheading:9794842-Histocompatibility Antigens Class II,
pubmed-meshheading:9794842-Humans,
pubmed-meshheading:9794842-Immune Tolerance,
pubmed-meshheading:9794842-Neoplasms
|
pubmed:year |
1998
|
pubmed:articleTitle |
The role of CD4+ T cell responses in antitumor immunity.
|
pubmed:affiliation |
Department of Oncology, Johns Hopkins University School of Medicine, 720 Rutland Avenue/Ross 364, Baltimore, MD 21205, USA.
|
pubmed:publicationType |
Journal Article,
Review
|